AR123724A1 - Composiciones y métodos para la prevención y/o tratamiento de la covid-19 - Google Patents
Composiciones y métodos para la prevención y/o tratamiento de la covid-19Info
- Publication number
- AR123724A1 AR123724A1 ARP210102795A ARP210102795A AR123724A1 AR 123724 A1 AR123724 A1 AR 123724A1 AR P210102795 A ARP210102795 A AR P210102795A AR P210102795 A ARP210102795 A AR P210102795A AR 123724 A1 AR123724 A1 AR 123724A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- polynucleotide
- covid
- prevention
- compositions
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 3
- 229940023146 nucleic acid vaccine Drugs 0.000 abstract 3
- 101710172711 Structural protein Proteins 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 108091007576 SARS-CoV-2 structural proteins Proteins 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a composiciones y métodos para la preparación, la fabricación y el uso terapéutico de vacunas de ácido nucleico que comprenden secuencias de polinucleótidos que codifican una o más proteínas estructurales de SARS-CoV-2 y variantes para el tratamiento, la mitigación, la mejora y/o la prevención de la COVID-19. Reivindicación 1: Un polinucleótido que codifica al menos una proteína estructural de SARS-CoV-2 o una variante de esta, caracterizado porque al menos una proteína estructural es la proteína espicular (S) y donde el polinucleótido comprende una primera región de secuencia, dicha primera región de secuencia comprende una secuencia de ácido nucleico que tiene al menos un 80% de identidad con un miembro del grupo que consiste en las SEQ ID nº 7, 20, 26, 27 y 32. Reivindicación 13: Una vacuna de ácido nucleico caracterizada porque comprende el polinucleótido de la reivindicación 12. Reivindicación 15: Una composición farmacéutica caracterizada porque comprende la vacuna de ácido nucleico de la reivindicación 14 y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3096009A CA3096009A1 (en) | 2020-10-09 | 2020-10-09 | Compositions and methods for the prevention and/or treatment of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123724A1 true AR123724A1 (es) | 2023-01-04 |
Family
ID=81077368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102795A AR123724A1 (es) | 2020-10-09 | 2021-10-07 | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR123724A1 (es) |
| CA (2) | CA3096009A1 (es) |
-
2020
- 2020-10-09 CA CA3096009A patent/CA3096009A1/en not_active Abandoned
-
2021
- 2021-01-26 CA CA3107232A patent/CA3107232A1/en active Pending
- 2021-10-07 AR ARP210102795A patent/AR123724A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA3107232A1 (en) | 2022-04-09 |
| CA3096009A1 (en) | 2022-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| BR112022015626A2 (pt) | Composição e métodos de vacinas de mrna contra infecção de novo coronavírus | |
| MX2022015132A (es) | Vacunas combinadas a base de acidos nucleicos. | |
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| RU2012139432A (ru) | Полипептиды | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
| AR109538A1 (es) | Vacuna contra la gripe porcina | |
| ATE103297T1 (de) | Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea. | |
| UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
| JP2008530975A5 (es) | ||
| AR127169A1 (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| ES2867049T3 (es) | Composiciones de vacuna que comprenden un virus de Zika mutante atenuado | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| AR088028A1 (es) | Proteinas h5, de h5n1 para un uso medicinal | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| ES2868627T3 (es) | Secuencias genómicas que codifican un virus de Zika mutante atenuado | |
| AR123724A1 (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae | |
| AR127311A1 (es) | VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA DELTA DEL SARS-CoV-2 | |
| AR112785A1 (es) | Composición de péptidos asociados a tumores proliferativos e inmunógeno anti-cáncer relacionado para el tratamiento de cánceres de pulmón y otros cánceres | |
| PH12020500194A1 (en) | Malaria vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |